Apollomics Inc Ordinary Shares - Class A APLM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $14.30
- Day Range
- $13.77–13.93
- 52-Week Range
- $0.00–42.12
- Bid/Ask
- $12.51 / $16.30
- Shares Outstanding
- 2.20M
- Market Cap
- $30.28M
- Volume/Avg
- 20 / 7,723
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.apollomicsinc.com
Valuation
|
Metric
|
APLM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.43 |
Price/Cash Flow | — |
Price/Earnings
APLM
Financial Strength
|
Metric
|
APLM
|
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 0.96 |
Interest Coverage | −169.58 |
Quick Ratio
APLM
Profitability
|
Metric
|
APLM
|
|---|---|
Return on Assets (Normalized) | −98.58% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
APLM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mtdcmnq | Bcrhm | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zjzlvlgs | Zxxmd | $63B | |||
| argenx SE ADR
ARGX
| Cqmqxsfq | Qmn | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gjpdczvg | Zqnghgl | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Yhmdxrlnq | Prnpxrq | $24B | |||
| BioNTech SE ADR
BNTX
| Jkbtkxrq | Ljd | $22B | |||
| Incyte Corp
INCY
| Mtdglyqyv | Jytmp | $21B | |||
| Moderna Inc
MRNA
| Xmxbdfr | Ygb | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Kcztrmjf | Qkk | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Zrmbpjbht | Lfy | $13B |
United States